|
In Remembrance
|
|
Join Date: Aug 2006
Location: Florida
Posts: 3,904
|
|
|
In Remembrance
Join Date: Aug 2006
Location: Florida
Posts: 3,904
|
thanks linda
Anymore about this? It sounds like something Steve Gill from UK was working on, doesn't it? He stayed a lot out the fray, still wanted to use Amgen in some capacity - heard that quite awhile back tho.
How interesting it is going to be to learn. i'm glad to see it, but suffer from cognitive dissonance - not from PD, just from mankind's failure to launch or similarly, launch with failure to tell --Will the NIH be quick about it? Do we allow ourselves to think that this is real and sometime soon?
I'm including this article received from Carolyn in pipeline email that reveals more unenforced and ignored regulations. It is not connected to the GDNF trial. Just more watchdog info.
20 Mar 2009 http://www.medicalnewstoday.com/articles/142956.php
Although paying finder's fees to researchers and clinicians to identify study participants could compromise the recruitment process and harm human lives, many medical schools fail to address this conflict of interest in their Institutional Review Board (IRB) policies.
Leslie Wolf, an associate professor of law at Georgia State University, studied the IRB policies posted on the Web sites of 117 medical schools that received National Institutes of Health funding. Among the study's findings, Wolf revealed that less than half of the IRB policies discuss finder's fees or bonus payments as conflicts of interest, where research sponsors pay members of the research team or clinicians to identify potential participants or for meeting predetermined enrollment targets.
paula
Quote:
Originally Posted by LindaH
This is what I remember from the presentation at the PAN Forum:
|
Quote:
Originally Posted by LindaH
At the Emerging Therapies session at the PAN Forum, Dr. Howard Federoff spoke about research on AAV2 virus delivery of GDNF. This was the viral delivery method used in the phase II Ceregene trial. He said it would involve "Convection Enhanced Delivery" (method used in the phase I infused GDNF Un. of Kentucky trials, but not in Amgen's) It gets the GDNF into the brain more efficiently. Also said additional areas of the brain would be targeted. A NINDS consortium has been researchiing viral vector delivery of GDNF in animal models and will be conducting a phase I clinical trial, possibly in Fall 2009. Hopefully more details will be coming....
|
__________________
paula
"Time is not neutral for those who have pd or for those who will get it."
|